A Multicenter, Phase 2 Study Evaluating IMC-A12 in Combination With Sorafenib as First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine progression free survival (PFS) in patients with
unresectable hepatocellular carcinoma who have received no prior systemic therapy when
treated with IMC-A12 administered every three weeks in combination with oral sorafenib
administered twice daily.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival (PFS)
Approximately 2 years
No
E-mail: ClinicalTrials@ ImClone.com
Study Director
ImClone LLC
United States: Food and Drug Administration
13931
NCT00906373
May 2009
June 2013
Name | Location |
---|---|
ImClone Investigational Site | New York, New York 10021 |
ImClone Investigational Site | Bakersfield, California 93309 |
ImClone Investigational Site | Decatur, Illinois 62526 |
ImClone Investigational Site | New Orleans, Louisiana 70121 |
ImClone Investigational Site | Philadelphia, Pennsylvania 19107 |
ImClone Investigational Site | Tucson, Arizona 85712 |
ImClone Investigational Site | Boston, Massachusetts 02135 |